Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer (Q36429614)

14 August 2017

1 reference

title

Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer (English)

1 reference

14 August 2017

0 references

1 reference

2

Edith A Perez

1 reference

14 August 2017

Alvaro Moreno-Aspitia

series ordinal

1

1 reference

PubMed ID

16556053

14 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

14 August 2017

1 reference

14 August 2017

1

1 reference

14 August 2017

6

1 reference

14 August 2017

755-762

1 reference

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

14 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.755

Role of formulation vehicles in taxane pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.755

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.755

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.755

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.755

21 January 2018

Identifiers

DOI

10.2217/14796694.1.6.755

1 reference

14 August 2017

1 reference

PubMed ID

16556053